Clinical Trial of Vormatrigine in Adult Patients With Epilepsy

Part of paid clinical trials in Miami Lakes, Florida.

Sponsor
Praxis Precision Medicines
Study ID
NCT07287163
Phase
PHASE3
Status
Enrolling By Invitation

Conditions

  • Epilepsy, Tonic-Clonic
  • Focal Seizure
  • Primary Generalized Seizure

Eligibility Criteria

Sex
ALL
Age
18 Years - 85 Years
Healthy Volunteers
Not accepted

Interventions

  • vormatrogine — DRUG
    Once daily oral

Study Details

Open Label Extension Clinical Trial of Vormatrigine in Adult Patients with Epilepsy

Key Dates

Start date
Oct 27, 2025
Status verified
Dec 2025
Primary completion
May 31, 2028
Completion
Dec 31, 2028

Study Design

Enrollment
700 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Open-label 30 mg/day vormatrogine for up to 2 years
    Participants who meet all eligibility criteria will receive 30 mg of vormatrogine for up to 2 years.

Primary Outcome Measure

To assess the safety and tolerability of vormatrigine in adults with focal or primary generalized tonic-clonic seizures [ Time Frame: Up to 2 years ]

Locations (9)

FacilityCityStateZIPSite coordinators
Praxis Research SiteMiami LakesFlorida33016-
Praxis Research SiteNaplesFlorida34116-
Praxis Research SiteLafayetteLouisiana70508-
Praxis Research SiteBethesdaMaryland20817-
Praxis Research SiteChesterfieldMissouri63005-
Praxis Research SiteAmherstNew York14226-
Praxis Research SiteMiddletownNew York10941-
Praxis Research SiteEl PasoTexas79912-
Praxis Research SiteHoustonTexas77058-

Find similar trials in Miami Lakes, FL

By research site
Praxis Research Site· Miami Lakes, FLPraxis Research Site· Naples, FLPraxis Research Site· Lafayette, LAPraxis Research Site· Bethesda, MDPraxis Research Site· Chesterfield, MOPraxis Research Site· Amherst, NY

Related Studies